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Edited by Maurice MontalAbstract Voltage-gated Naþ channel (INa) is expressed under
culture conditions in human smooth muscle cells (hSMCs) such as
coronary myocytes. The aim of this study is to clarify the
physiological, pharmacological and molecular characteristics of
INa expressed in cultured hSMCs obtained from bronchus, main
pulmonary and coronary artery. INa, was recorded in these hSMCs
and inhibited by tetrodotoxin (TTX) with an IC50 value of
approximately 10 nM. Reverse transcriptase/polymerase chain
reaction (RT-PCR) analysis of mRNA showed the prominent
expression of transcripts for SCN9A, which was consistent with
the results of real-time quantitative RT-PCR. These results
provide novel evidence that TTX-sensitive Naþ channel expressed
in cultured hSMCs is mainly composed of Nav1.7.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The voltage-gated Naþ channel (INa) exists in a variety of
excitable cells including nerves, heart and skeletal muscle. In
response to depolarizing stimuli, the channels open and play an
essential role in the rising phase of action potential, which is
important for impulse generation and conduction. INa is an in-
tegral membrane protein composed of a and auxiliary b-sub-
units [1–3]. Several a-subunit Naþ channel genes have been
cloned and functionally analyzed in heterologous expression
systems [1,2]. Until now, ten types of a-subunit Naþ channel
genes denoted as SCN1A to SCN11A [1,3] have been identiﬁed,
and are distributed among mammalian cells.
INa is also identiﬁed in several types of freshly isolated smooth
muscle cells (SMCs) including vascular, urinary and gastroin-
testinal SMCs [4–8]. The jejunal circular human SMCs (hSMCs)
express a tetrodotoxin (TTX)-insensitive INa [9], probably
Nav1.5 known as the Na
þ channel gene in heart. However, INa
expressed in SMCs [4–8] is a TTX-sensitive type, indicating that* Corresponding author. Fax: +81-3-3814-0021.
E-mail address: masamasa@pb4.so-net.ne.jp (T. Nakajima).
Abbreviations: INa, voltage-gated Na
þ channel; SMCs, smooth muscle
cells; TTX, tetrodotoxin; RT-PCR, reverse transcriptase/polymerase
chain reaction
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.04.092diﬀerent types of a-subunit Naþ channel genes may be involved.
Esophageal hSMCs express TTX-sensitive INa;Nav1.4 [10]. Ex-
istence of INa has also been reported in cultured hSMCs such as
bronchial (hBSMCs) [11], coronaryarterial (hCASMCs) [12,13],
pulmonary arterial (hPASMCs) and aortic SMCs [14–16], but
the types of INa expressed in cultured hSMCs remain unknown.
Therefore, we investigated the molecular, pharmacological
and physiological characteristics of INa; expressed under cul-
ture conditions in hSMCs. Here, we show that cultured
hSMCs possess TTX-sensitive INa mainly composed of Nav1.7.2. Materials and methods
2.1. Cell preparation
Culture cells isolated from normal human bronchus (hBSMCs), main
pulmonary artery (hPASMCs) and large coronary artery (hCASMCs)
were purchased from Clonetics Corporation (San Diego, USA). The
hSMCswere cultured inmedium supplementedwith 5% fetal calf serum,
human epidermal growth factor (0.5 lg/ml), insulin (5 mg/ml), human
ﬁbroblast growth factor (1 lg/ml), gentamycin (50 lg/ml), and ampho-
tericin B (0.05 lg/ml) [SmGM-2 Buﬀer-Kit, Clonetics] in an atmosphere
of 5% CO2 and 95% air at 37 C. At conﬂuence, the cells were passaged
using 0.05% trypsin in 0.02% EDTA, and they were subcultured in the
samemedium.Cells isolatedby trypsin just before conﬂuence at passages
3–7were used for later experiments. The cells were identiﬁed as SMCsby
the expression of a-actin as shown previously [17].
2.2. Solutions and drugs
The composition of control Tyrode solution was as follows (in mM):
NaCl 136.5, KCl 5.4, CaCl2 1.8, MgCl2 0.53, glucose 5.5 and HEPES–
NaOH buﬀer 5.5 (pH 7.4). To block Kþ currents, the patch pipette
contained (in mM): CsCl 140, EGTA 10, MgCl2 2, Na2ATP 3,
guanosine-50-triphosphate (GTP, sodium salt; Sigma) 0.1, and HE-
PES–CsOH buﬀer 5 (pH 7.2). 4-aminopyridine (4-AP, 4 mM), a
voltage-dependent Kþ channel blocker, tetraethylammonium (2 mM),
a Ca2þ-activated Kþ current blocker, and Ba2þ (1 mM), a blocker of
an inwardly rectiﬁer Kþ current [18], were added to the control Tyrode
solution. In addition, nifedipine (1 lM) was included into the bathing
solution to block the voltage-dependent L-type Ca2þ currents. In the
NMDGþ solution, extracellular Naþ was replaced with equimolar N-
methyl-D-glucamine (NMDGþ). All experiments were performed at
room temperature (20–25 C).
2.3. Recording technique and data analysis
Membrane currents were recorded with tight-seal whole-cell clamp
techniques using a patch-clamp ampliﬁer (EPC-7, List Electronics,
Darmstadt, Germany) as previously described [19–21].
The steady-state inactivation was estimated using double-pulse pro-
tocol. Conditioning voltage pulses (500 ms in duration) of various
membrane potentials were applied from a holding potential of )80 mV.
At 10 ms after the end of each conditioning pulse, a test pulse of +0 mVation of European Biochemical Societies.
Table 1
PCR primers used for ampliﬁcation of voltage-gated Naþ channel genes
Gene symbol Channel Size (bp) Sequence (50–30)
SCN1A Nav1.1 298 Sense GACAGCATCAGGAGGAAAGG
Antisense TGGTCTGACTCAGGTTGCTG
SCN2A Nav1.2 194 Sense ATCCAGAGGGCTTACAGACG
Antisense ATCATACGAGGGTGGAGACG
SCN3A Nav1.3 354 Sense AATTCTGTGGGGGCTCTAGG
Antisense AGCAGCAAGGTTGTCTGAGC
SCN4A Nav1.4 502 Sense CAGGCATCTTCACAGCAGAG
Antisense ACCATGAGGAAGACGGTGAG
SCN5A Nav1.5 618 Sense ACCATCGTGAACAACAAGAGCC
Antisense GGCAGCCAGCTTGACAATACAC
SCN6A Nax 449 Sense AAGAGGTGTCTGGGCAGGAT
Antisense GACCAGCATCTGTCCTGTTG
SCN8A Nav1.6 599 Sense GAGGTGAAGCCTCTGGATGA
Antisense CGGATGGTCTTTCTCTGCTC
SCN9A Nav1.7 403 Sense GAGGCCTGTTTCACAGATGG
Antisense TGGGGCCAAGATCTGAGTAG
SCN10A Nav1.8 453 Sense CTTGGGCTTTCCTCTCACTG
Antisense AGGCGAGGCCIAGAAAAGAC
SCN11A Nav1.9 343 Sense GGCTGTGCGTTAAGAAGGTC
Antisense ACCCTGAGCACTCTGAAGGA
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pulses was plotted against each conditioning voltage. From current–
voltage (I–V) data, the steady-state activation curvewas derivedbyusing
the following equation: gNa¼ INa/[(Vm )ENa)], where INa is the peak
current amplitude at each membrane potential (Vm), gNa is the chord
conductance, and ENa is the Na
þ-equilibrium potential. ENa was ob-
tained from I–V curve, where the I–V curve crossed over the zero line.
The time course of recovery from inactivation was measured by double-
pulse protocols. The ﬁrst (PI, 50 ms) and the second pulse (PII, 50 ms)
with variable interpulse intervals were applied from )80 to +0 mV.
Data were expressed as the meansS.E. Student’s t-test was used
for statistical analysis and P < 0:05 was signiﬁcant.
2.4. RNA extraction, RT-PCR and real-time quantitative RT-PCR
Total cellular RNAwas extracted using ISOGEN (NipponGene, To-
kyo). For reverse transcriptase/polymerase chain reaction (RT-PCR),
complementary DNA (cDNA) was synthesized from 1 lg of total RNA
with reverse transcriptase with random primers (Toyobo, Osaka) as
shown previously [18]. The reaction mixture was then subjected to PCR
ampliﬁcation with speciﬁc forward and reverse oligonucleotide primers
for 30 cycles consisting of heat denaturation, annealing, and extension.
PCR products were size-fractionated on 2% agarose gels and visualized
under UV light. Primers were chosen based on the sequence of human
SCNl-6A and 8A–11A as shown in Table 1. Table 1 also shows the Naþ
channel protein created by each SCN gene. Total RNA of human fetal
brain, skeletal muscle and heart (Toyobo, Osaka) was used for positive
control.
Real-time quantitative RT-PCR was performed with the use of real-
time Taq-Man technology and a sequence detector (ABI PRISM
7000, Applied Biosystems, Foster City, CA) [22]. Gene-speciﬁc primers
and Taq-Man probes were used to analyze transcript abundance. The
18S ribosomal RNA level was analyzed as an internal control and used
to normalize the values for transcript abundance of SCN family genes.
We performed six independent experiments.3. Results
3.1. Voltage-gated Naþ channels expressed in cultured hSMCs
Fig. 1A shows a typical recording of INa expressed in
hBSMCs. The cell was held at )80 mV and the commandvoltage pulses were applied to various membrane potentials.
At potentials more positive than )40 mV, a transient inward
current was elicited (Fig. 1A). The current–voltage (I–V) re-
lations measured at the peak of the inward current are shown
in B. The peak amplitude of the inward current was observed
at approximately )10 mV. The time course of the inactivation
of the current was well ﬁtted as a single exponential with s
value of 1.1 0.2 ms (n ¼ 5) at +0 mV. Replacement of Naþ
with NMDGþ, an impermeable cation, completely abolished
the inward current (Fig. 1C). Nifedipine (10 lM, n ¼ 3) did
not inhibit it, but TTX (1 lM) completely blocked it (Fig. 1D).
TTX inhibited it concentration-dependently with an IC50 value
of 5.9 nM (n ¼ 5) in hBSMCs as shown in Fig. 1E. INa was
detected in 38% of the total cells tested(n ¼ 95).
Similarly, INa was recorded in cultured hPASMCs (Fig. 2A,
20%, 10 out of 50 cells examined) and hCASMCs (Fig. 2B,
15%, 6 out of 40 cells). TTX inhibited INa expressed in cultured
hCASMCs with an IC50 value of 6.5 nM (n ¼ 4).
3.2. Voltage-dependent characteristics of INa
Fig. 2C shows typical examples of INa recordings used to
obtain the steady-state inactivation protocol in hBSMCs (see
Section 2). The relation between membrane potentials and the
Vh value (Fig. 2C) was ﬁtted to the following equation
(Boltzmann equation) using the least-squares methods:
IðV Þ=Imax ¼ l=f1þ exp½ðV  VhÞ=k]}, where V is the mem-
brane potential in mV, Vh is the membrane potential at half
maximum, and k is the slope factor. The value of Vh and k was
)37 5 mV and 11.6 3 mV (n ¼ 4), respectively. The steady-
state activation curves were obtained from the conductance
(gNa) and also ﬁtted by Boltzmann equation (Fig. 2D). The
value of Vh and k was )16 5 and )5.3 1.0 mV (n ¼ 4), re-
spectively. The overlap of the steady-state activation and in-
activation curve at potentials more positive than )40 mV
determines the INa window currents. Fig. 2E and F show the
time courses of recovery from the inactivation of INa. By ﬁtting
Fig. 1. INa expressed in cultured human bronchial SMCs. The original
current traces elicited by depolarizing pulses are indicated in A. The
current–voltage (I–V) relations measured at the peak are illustrated in
B. The I–V relations are shown after the leakage currents were sub-
tracted. (C) Eﬀects of replacement of extracellular Naþ with NMDGþ.
The current traces in C were elicited from a holding potential of )80 to
+0 mV. (D) Eﬀects of nifedipine and TTX on the transient inward
current. (E) Concentration-dependent inhibition of INa by TTX. The
cells were held at )80 mV, and command voltage-pulses to +0 mV (100
ms in duration) were applied at 0.2 Hz. The inhibitory eﬀect of TTX on
the current amplitude measured at the peak is plotted against various
concentrations of TTX Data are shown as means S.E. (n ¼ 5) and ﬁt
by a Michaelis–Menten simple bimolecular model: % inhibition¼ 100/
{1+ (IC50/[TTX])}, where IC50 is 50% inhibitory concentration for
TTX. The data were best ﬁt with an IC50 value of 5.9 nM.
Fig. 2. (A) and (B) INa expressed in cultured hPASMCs (A) and
hCASMCs (B). The cells were held at )80 mV and command voltage
pulses to +0 mV were applied. (C) and (D) Steady-state activation and
inactivation curves for INa expressed in hBSMCs. The typical original
current traces for obtaining the steady-state inactivation curves are
indicated in C and the data were ﬁtted by Bolzmann equation (D). In
D, the data represent means S.E. value obtained from four diﬀerent
cells. Open circles (steady-state activation curve), closed circles (steady-
state inactivation curve). (E) and (F) Recovery from inactivation for
INa. The typical original current traces are shown in E. The data were
ﬁtted by single exponential function, where the time constant of re-
covery from inactivation was 23.9 ms in this cell (F).
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constants were calculated as 24 5 ms (n ¼ 4).
3.3. Expression of voltage-gated Naþ channel (SCN) in
cultured hSMCs
We investigated the expression of SCN channel family
members (SCN1A-11A) except SCN7A mRNA in cultured
hSMCs, because SCN6A and 7A are probably the same gene
[23]. The amplitude of SCN cDNA fragments was of predicted
molecular size, identical to cDNA fragments ampliﬁed from
reversely transcripted mRNA. The transcript of SCN5A was
only detected in hPASMCs, and that of SCN3A was detected
only in hCASMCs. The transcripts of SCN1A, 2A, 4A, 6A,
10A, and 11A (data not shown) were not detected in these
cells. The transcript of SCN8A was detected weakly in
hBSMCs and hPASMCs. The deﬁnite transcript of SCN9A
was detected in all of the cells. A positive control for SCN1A–3A, SCN4A and SCN5A–6A was observed in human fetal
brain, skeletal muscle and heart, respectively.
Expression of SCN channel family member genes (SCN4A–
5A, 8A–9A) was also investigated by real-time quantitative
RT-PCR. Transcript levels were normalized to 18S ribosomal
housekeeping gene. As shown in Fig. 3B, expression levels of
SCN9A mRNA were much higher than those of SCN8A. The
transcripts of SCN4A and SCN5A were much less than those
of SCN9A.4. Discussion
The present study demonstrated the presence of INa under
culture conditions in hSMCs, which was consistent with the
previous papers [11–14]. TTX inhibited it concentration-
dependently with an IC50 value of approximately 10 nM.
These ﬁndings indicate that INa expressed in cultured hSMCs
closely resembles TTX-sensitive INa found in human brain and
skeletal muscle, but is diﬀerent from that found in human
heart [1]. Similar TTX-sensitive INa has been reported in
Fig. 3. Expression of INa genes detected by RT-PCR in cultured
hSMCs. (A) RT-PCR. As a positive control, SCN1A–3A were ob-
served in human fetal brain. SCN4A and 5A–6A were observed in
human skeletal muscle and human heart, respectively. N, negative
control; B, human fetal brain; H, human heart; Sk, human skeletal
muscle; S, cultured hSMCs (hBSMCs, hCASMCs and hPASMCs). (B)
Real-time quantitative RT-PCR in hBSMCs. The expression levels of
SCN channel genes were normalized to those of the 18S ribosomal
RNA levels. Data are means S.E. from six independent samples.
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molecular techniques, human jejunal circular and esophageal
SMCs have been shown to express a TTX-insensitive INa gene,
SCN5A [9], and a TTX-sensitive Naþ channel gene, SCN4A
[10], respectively. In the present studies using RT-PCR,
SCN5A was detected in hPASMCs. However, it is unlikely
that Nav1.5 contributes to form INa in these cells because low
concentration of TTX could completely inhibit INa. And,
SCN4A did not exist. Alternatively, the prominent expression
of SCN9A was detected in all types of cultured hSMCs ex-
amined. TTX-sensitivity of Naþ channels is determined by
whether one amino acid in SS2 regions of repeat I is aromatic
or not, and the amino acid (Y374) is aromatic, suggesting that
Nav1.7 belongs to TTX-sensitive INa [24]. Thus, these results
suggest that Nav1.7 is mainly responsible for INa expressed in
cultured hSMCs, which was consistent with the results of real-
time quantitative RT-PCR analysis.
INa expressed in cultured hSMCs was activated at potentials
greater than )40 mV and displayed a half inactivation voltage
(Vh) of approximately )37 mV, and the window current was
observed at potentials more positive than )40 mV. During the
repolarization period of 10 ms used in our protocol, parts of INa
can recover, and the residual current may aﬀect the inactivationcurves. But, it is negligible at potentials negative than )30 mV
due to the small amplitude of INa. Thus, these values are more
positive than those reported for INa reported in muscle, nerves
[23,25]. and freshly isolated SMCs [7–9], proposing that it has
atypical characteristics of INa. But, since the culturedSMCsused
here had a membrane potential of approximately )40 mV as
described previously [18], it is reasonable that INa expressed in
cultured hSMCs contributes to form membrane potentials and
muscle excitability in these cells. In addition, it is likely that small
depolarizing stimuli open INa furthermore, thereby inducing an
increase of Na inﬂux and intracellular Naþ concentration
([Naþ]i). The increase in [Naþ]i alters the driving force for Naþ,
the rate ofmovement ofNaþ ions by theNaþ/Kþ pumpand then
the Naþ/Ca2þ exchanger, which may subsequently raise intra-
cellular Ca2þ concentration ([Ca2þ]i) in these cells.
Expression of Nav1.7 has been found at high levels in pe-
ripheral nervous systems and neuroendocrine cells [26,27],
which is involved in cell excitability and secretion. Recently, it
has been reported in rat and human prostate cancer cell lines,
pheochromocytoma and thyroid gland tumor [28]. Physical
signiﬁcance of INa expressed in these tumor cells remains un-
clear, but it may be related to the tumor invasion,metastasis and
cell proliferation. INa has been identiﬁed in various types of
phasic SMCs [8], which usually generate action potential. On the
other hand, it is not expressed in freshly isolated tonic SMCs
such as human coronary artery and bronchial muscle [11–13], in
contrast to the cultured cells [11–14], though expression of INa
has been reported only in rabbit pulmonary arterial cells [6].
Thus, it is likely that INa expressed in cultured hSMCs is limited
to the culture conditions, where cellular dediﬀerentiation and
proliferationmaybe involved [13,15]. Expression of INa could be
found in parts of the cells examined in this study, whichmay also
support this notion. However, these changes may be occurred
under various pathophysiological conditions such as vascular
injury, atherosclerosis and asthma [29–32]. Therefore, the pos-
sible expression of INa under these conditions is worth consid-
ering, and further studies are necessary to clarify the
physiological signiﬁcance of the channel.
In conclusion, the present study provides novel evidence that
TTX-sensitive Naþ channel is expressed under culture condi-
tions in hSMCs, mainly composed of Nav1.7.References
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